Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy
Journal of Obstetrics and Gynaecology Research, 06/01/2012
Clinical Article
Kunito S et al. – The long–term results suggest CPT–P as a candidate in first–line chemotherapy for CCC in not only stage I, but also in optimally debulked stage II–IV patients with pT1/pT2 disease.
Methods- Authors performed a retrospective review of 31 patients with CCC who were treated with CPT–P between 1996 and 2004.
- The median follow–up period was 91 months.
- The estimated 8–year overall survival (OS) rate in all patients was 64.5%, while the rate in 18 stage I, 21 stage I/II, and 10 stage III/IV patients was 88.9%, 85.7%, and 20.0%, respectively.
- The estimated 8–year OS rate in patients with pT1/pT2 disease was 87.0%, while the 3–year OS rate in patients with pT3 disease was 0%.
- Univariate analysis using the log–rank test revealed that Eastern Cooperative Oncology Group performance–status 1, pT3 stage, and presence of residual disease (stage II–IV) were significantly correlated with shortened patient survival.
- Multiple regression analysis revealed that pT3 predicted worse OS in patients with CCC than pT1 (P < 0.001) or pT2 disease (P < 0.005).
